Related Experiment Videos
Fluoroquinolones in the Treatment of Meningitis
Philippe Cottagnoud1, Martin G. Täuber
1*Department of Internal Medicine, Inselspital, Freiburgstrasse, 3010 Bern, Switzerland. pcottagn@insel.ch
Abstract:
The continuous increase of resistant pathogens causing meningitis has limited the efficacy of standard therapeutic regimens. Due to their excellent activity in vitro and their good penetration into the cerebrospinal fluid (CSF), fluoroquinolones appear promising for the treatment of meningitis caused by gram-negative microorganisms, ie, Neisseria meningitidis and nosocomial gram-negative bacilli. The newer fluoroquinolones (moxifloxacin, gemifloxacin, gatifloxacin, and garenoxacin) have excellent activity against gram-positive microorganisms. Studies in animal models and limited clinical data indicate that they may play a future role in the treatment of pneumococcal meningitis. Analysis of pharmacodynamic parameters suggests that CSF concentrations that produce a C(peak)/minimal bactericidal concentration (MBC) ratio of at least 5 and concentrations above the MBC during the entire dosing interval are a prerequisite for maximal bactericidal activity in meningitis. Of interest, newer fluoroquinolones act synergistically with vancomycin and beta-lactam antibiotics (ceftriaxone, cefotaxime, meropenem) against penicillin-resistant pneumococci in experimental rabbit meningitis, potentially providing a new therapeutic strategy. Clinical trials are needed to further explore the usefulness of quinolones as single agents or in combination with other drugs in the therapy of pneumococcal meningitis.
Insights
Fluoroquinolones show promise for treating meningitis, especially newer agents effective against resistant gram-positive and gram-negative bacteria. Combinations with other antibiotics may offer new strategies for difficult-to-treat pneumococcal meningitis.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Rising antimicrobial resistance necessitates novel therapeutic strategies for meningitis.
- Standard treatments are becoming less effective against resistant bacterial strains.
- Meningitis remains a significant cause of morbidity and mortality worldwide.
Purpose of the Study:
- To evaluate the potential of fluoroquinolones in treating meningitis caused by resistant pathogens.
- To explore the efficacy of newer fluoroquinolones against gram-positive and gram-negative meningitis pathogens.
- To investigate pharmacodynamic parameters and synergistic effects for optimal meningitis treatment.
Main Methods:
- In vitro susceptibility testing of fluoroquinolones against meningitis pathogens.
- Pharmacodynamic analysis of cerebrospinal fluid (CSF) drug concentrations.
- Evaluation of fluoroquinolone efficacy in animal models of meningitis.
- Assessment of synergistic activity with other antibiotics against resistant strains.
Main Results:
- Fluoroquinolones demonstrate excellent in vitro activity and CSF penetration against gram-negative meningitis pathogens.
- Newer fluoroquinolones show efficacy against gram-positive organisms, including resistant Streptococcus pneumoniae.
- Pharmacodynamic targets (Cpeak/MBC ratio ≥ 5) are crucial for bactericidal activity in meningitis.
- Synergistic effects observed with vancomycin and beta-lactams against resistant pneumococci in experimental models.
Conclusions:
- Fluoroquinolones are promising agents for treating gram-negative meningitis and potentially pneumococcal meningitis.
- Optimizing CSF drug concentrations is key for effective fluoroquinolone therapy.
- Combination therapy with fluoroquinolones may offer new treatment avenues for resistant meningitis.
- Further clinical trials are essential to confirm the role of fluoroquinolones in meningitis treatment.